Trial Profile
Open label study to establish the efficacy of intravenous loading doses of Ibandronate 6 mg in patients with lung cancer and skeletal metastases experiencing moderate to severe bone pain: NVALT 9.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2014
Price :
$35
*
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Bone metastases
- Focus Therapeutic Use
- Acronyms NVALT-9
- 20 Feb 2009 New trial record